Possessing extensive executive experience in accounting and finance, Peter Culpepper serves as the chief operating officer and chief financial officer of Provectus Biopharmaceuticals. Recently, Peter Culpepper’s company announced the receipt of a United States patent that will extend protection to the manufacturing process of PV-10, a trial-stage drug that has been patented since 2013. The new patent prohibits the use of any alternative raw materials to create the same active ingredient found in PV-10.
With coverage until at least 2031, the new patent keeps the company’s intellectual property safe as it tests its proprietary drug through clinical trials, including a pivotal phase 3 trial examining the efficacy of PV-10 in the treatment of melanoma.
Co-inventors on the patent include scientists from Cambrex Charles City, a subsidiary of Cambrex Corporation. These scientists partnered with Provectus to develop the unique manufacturing process that makes it possible to produce the active ingredient in PV-10, and their inclusion on the patent is a small recognition of the contribution that they have made.